ABSTRACT Traumatic brain injury (TBI) produces a rapid and excessive elevation in extracellular glutamate that induces excitotoxic brain cell death. The peptide neurotransmitter N-acetylaspartylglutamate (NAAG) is reported to suppress neurotransmitter release through selective activation of presynaptic Group II metabotropic glutamate receptors. Therefore, strategies to elevate levels of NAAG following brain injury could reduce excessive glutamate release associated with TBI. We hypothesized that the NAAG peptidase IIlhih itor. ZJ-43 would elevate extracellul~lr NAAG levels and reduce ext",cellular levels of amino acid neurotransmitters following Tl3l by a Group II metabotropic gluta mate receptor (mGluR)-mcdiated mechanism. Dialysate levels ofNAAG, glutamate, aspartate and GABA from the dorsal hippocampus were elevated after TBI as measured by ill vivo microdialysis. Dialysate levels ofNAAG were higher and remained elevated in the ZJ-43 treated group (50 mg/kg, i.p.) compared to control. ZJ-43 treatment also reduced the rise of dialysate glutamate, aspartate, and GAB A levels. Co-administration of the Group II mGluR antagonist, L Y34 1495 (I mg/kg, i.p.) partially blocked the effects of ZJ-43 on dialysate glutamate and GABA suggesting that NAAG effects are mediated through mGluR activation. The results are consistent with the hypothesis that inhibition ofNAAG peptidase may reduce excitotoxic events associated with TBI.
INTRODUCTION
Traumatic brain injury (TBI) is a serious health problem that results in more than 230,000 hospitalizations and 50,000 deaths per year in the USA (NIH, (999) . However, no truly efficacious and approved therapies are currently available for the treatment ofTBI. The search for neurochemical pathways of secondary injury after TBI and subsequent development of therapeutic interventions has implicated glutamate excitotoxicity as an important mechanism causing neuronal damage through excessive receptor activation. For example, extracellular glutamate is elevated immediately after the TBI (Faden et aI., 1989; Katayama et aI., 1990; Globus et aI., (995) and significantly contributes to delayed neuronal cell death following TBI (Smyth et aI., 2005a (Smyth et aI., , 2005b . Pharmacological blockade of glutamate receptors early after TBI improves outcome in laboratory animals (e.g., Hayes et aI., 1988 , Faden et aI., 1989 Kawamata et aI., 1992) . Although laboratory results targeting glutamate excitotoxicity have often been impressive, translation of this strategy into clinical application, particularly the use of receptor antagonists, remains overwhelmingly disappointing (Bullock et aI., 1999; Narayan et aI., 2002) . As an alternative strategy, the present study examines the possibility of reducing excessive glutamate release following TBI by manipulating N-acetylaspartylglutamate (NAAG), an endogenous neuropeptide involved in modulating glutamate release.
NAAG is an abundant peptide neurotransmitter found in millimolar concentrations in the mammalian central nervous system (Coyle et aI., 1997; Neale et aI., 2000) . NAAG selectively activates the Group II metabotropic glutamate receptor subtype 3 (mGluR3), with about IO-fold less efficacy at mGluR2 (Wroblewska et aI., 1993 (Wroblewska et aI., , 1997 Schweitzer et aI., 2(00) . Acting at the presynaptic group II mGluR, NAAG has been shown to reduce cAMP levels (Wroblewska et aI., 1993 (Wroblewska et aI., , 1997 , decrease voltageregulated calcium conductance (Bischofberger and Schild, 1996) and importantly to reduce the synaptic release of glutamate and GABA (Zhao et aI., 2001; Xi et aI., 2002; Garrido-Sanabria et al.. 2004) .
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Therefore inhibiting the hydrolysis ofNAAG may be an alternative strate!,,), to attenuate glutamate excitotoxicity (reviewed in Neale et aI., 2000; Zhou et aI., 2005) .
Synaptically released NAAG is rapidly hydrolyzed to form glutamate and N-acetylaspartate (NAA) by at least two peptidases, glutamate carboxypeptidase II and III (Luthi-Carter et aI., 1998; Bzdega et aI., 2004) . Potent NAAG peptidase inhibitors have been synthesized by two research !,'!'oups (Jackson et al., 1996; Jackson & Slusher, 2001; Rong et aI., 2002; Kozikowski et aI., 2001 Kozikowski et aI., , 2004 . These peptidase inhibitors were shown to be neuroprotective in a number of glutamate excitotoxicity models (reviewed in Neale, et aI., 2005) including ischemic-hypoxic damage (Slusher et al. 1999) , inflammatory pain and allodynia (Yamamoto et aI., 200la; , diabetic neuropathy , amyotrophic lateral sclerosis (Ghadge et aI., 2003) and phencyclidine induced schizophrenia-like behaviors (Olszewski et aI., 2004) . Excess glutamate release has been implicated in each of these models of human pathological conditions. Moreover, recent studies found that systemic administration (immediate post-injury plu, repeated dosing at R and Iii hr post-injury) of ZJ-43, a novel NAAG peptidase inhibitor, significantly reduced TBI-induced neuron and astrocyte cell death following lateral fluid percussion in rats (Zhong et aI., 2005) . The selective Group II mGluR antagonist, L Y34 1495, completely abolished the cell death attenuation of the NAAG peptidase inhibitor. These data are consistent with the hypothesis that NAAG peptidase inhibitors augment an endogenous protective mechanism that reduces e,ciloloxic c\ ents mediated by NAAG activation of group II mGluRs.
In this report, we combined the fluid percussion model and a modified microdialysis technique to lest the hypothesis that following TBI, NAAG peptidase inhibition would increase extracellular NAAG levels and in tum reduce the release of glutamate and other neurotransmitter such as aspartate and GABA from neurons by a Group II mGluR-mediated mechanism.
MATERIALS AND METHODS

Animals:
Forty-three male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 364 ±23g were used for this study. The animals were housed in individual cages in a temperature (22°C) and humidity-controlled (50% relative) animal facility with a 12-hr light/dark cycle (light cycle 06:0011 8:00 hr). Water was continually available. The Institutional Animal Care and Use Committee at the University of California at Davis approved all animal procedures in these experiments.
ZJ-43 preparation and administration:
ZJ-43 (C"H 2o N 2 0" Mol. WI. 304.2964) was synthesized according to the published methods (Kozikowski et aI., 2004) . ZJ-43 was dissolved in saline (50 mg/mL). ZJ-43 (50 mglkg) or saline (equal volume) were injected i.p. 15 minutes prior to lateral fluid percussion TBI (n=9 per group). This dose was chosen based on a previous study in which 50 109/kg of ZJ-43 produced optimal protection in the same TBI model (Zhong et aI., 2005) . To test the hypothesis that the effect ofZJ-43 may be mediated by augmented NAAG activation of Group II mGluR, an additional group was co-administered ZJ-43 (50 mg/kg) and the Group II mGluR antagonist, LY341495 (I mg/kg, i.p.), which was predicted to abolish any effects ofZJ-43 on neurotransmitter levels (Kingston et aI., (998) .
Surgery:
Rats were anesthetized with 4% isoflurane in a 2: 1 nitrous oxidefoxygen mixture, intubated, and mechanically normoventilated with a rodent volume ventilator (Harvard Apparatus model 683, Holliston, MA) with isoflurane reduced to 2%. Rats were mounted in a stereotaxic frame, a scalp incision made along the midline, and a 4.8mm diameter craniectomy was performed on the left parietal bone (centered at 5 -4.5 mm bregma and lefllateral 3.0 mm). A rigid plastic injury tube (modified Leur-Ioc needle hub, 2.6 mm inside diameter) was secured over the exposed, intact dura with cyanoacrylate adhesive. Two skull screws (2.1 mm diameter, 6.0 mm length) were placed into burr holes, I mm rostral to Breb'l11a and I mm caudal to Lambda. A second scalp incision was made from the midline to the left transversely, the soft tissues and temporalis muscle divided and reflected, and a small burr hole was made on the left temporal bone. A modified guide cannula was angled at45 deb ... ee from vertical and inserted into the burr hole with its distal end protruding 1 mm into the brain. The assembly was secured to the skull with cranioplastic cement (Plastics One, Roanoke, VA). The depth of the microdialysis probe (2 mm CMNI2, CMA Microdialysis, Solna, Sweden) into the brain limited by an 8 mm spacer made from PE 1 00 tubing between the microdialysis probe and the guide cannulae. Rats remained ventilated with isoflurane reduced to 1 % in a 2: 1 nitrous oxide/oxygen mixture throughout the entire dialysis sampling period. Rectal temperature was continuously monitored and maintained within normal ranges during surgical preparation by a feedback temperature controller pad (CWE model TC-I 000, Ardmore, PAl.
Ninety minutes prior to TBI, the microdialysis probe was inserted through the guide cannula for optimal placement of the dialyzing membrane within the CA3 region of the left dorsal hippocampus with the tip of the dialysis membrane positioned at the following coordinates: AP: -4.5; L: 4.7; V: -4.1 mm from bregma according to the rat atlas of Paxinos and Watson (1998) . The probe was continuously perfused with Ringers solution at a constant flow rate of 2 IlUmin. Microdialysis sample collection was adjusted to allow for dead space in the probe and exit tubing (approximately 12 ilL, which cleared in 6 min). The probe was removed I min prior to TBI and replaced immediately after TBI. An additional control group was included to isolate the effects of microdialysis probe removal and reinsertion (probereinsertion control) on amino acid concentrations in uninjured rats (n=6). In this group, animals were treated identically to all other groups with the exception that no drug was delivered and TBI was not administered.
Dialysis sampling aliquots were collected every 15 minutes for 135 min after TBI and immediately frozen in powdered dry ice. Frozen microdialysate vials were later analyzed for NAAG, glutamate, aspartate, and GABA. The calculated probe efficiency for glutamate recovery was approximately 5-6% 6 when sampling from a 1 mM stock concentration of glutamate. However, dialysate amino acid levels reponed in the present study are not corrected for ill vitro rates of recovery because such calibration is not directly applicable to in vivo sampling (Hsiao et aI., 1990; Parsons and Justice, 1994) . The location of the microdialysis probe was verified histologically in each animal at the end of the experiment.
Induction of TOI:
Experimental TBI was produced using a fluid percussion device (VCU Biomedical Engineering, Richmond, VA) (Dixon et aI., 1987) The rats were disconnected from the ventilator, the injury tube connected to the fluid percussion cylinder, and a moderate fluid percussion pulse (range: 2.22 -2.35 ATM) was delivered within ten seconds. Immediately after TBI rats were ventilated with 1% isoflurane in a carrier gas mixture (2: I nitrous oxide/oxygen) for the duration of the experiment.
NAAG assay methods:
NAAG in dialysate samples was analyzed by radioimmunoassay. This method allows measurement of picomole amounts ofNAAG microdialysis samples. A 5-point standard curve was generated using
["H)NAAG, revealing a linear relationship with high correlation (Fig. I B) . Antibody to NAAG was produced in rabbits by repeated immunizations with NAAG coupled to thyroglobulin or to colloidal gold. Specificity of serum was detennined by comparing competitive displacement curves for NAAG and several related molecules (N-acetylaspartate, aspartyl glutamate, aspartate, and glutamate).
The radioimmunoassay was perfonned using protein A -agarose (Roche). Ninety microliters of protein A -agarose suspensions in microfuge tubes, were washed with 900 ilL PBS, and sedimented at 2500 x g for 15 seconds. The pellet was resuspended with NAAG antisera, diluted I: 300 with PBS, and incubated for 4 hours or overnight on orbital shaker at 4" C. The mixture was sedimented as above, and washed with PBS. The pellet was then resuspended in 100 ilL of [lHJ NAAG (25, The pellet was washed three times with PBS. Agarose was then transferred to scintillation vials after resuspension with 0.2M HCI. The tritium bound to protein A -agarose was counted by liquid scintillation, and bound radioactivities of unknown samples were compared to the standard curve.
Quantification of amino acid concentrations:
Glutamate and aspartate were detennined by precolumn derivatization of a 10 ilL dialysate sample with o-phtaldialdehyde/mercaptoethanol reagent and separation by reversed-phase HPLC on a Biophase ODS 5 11M particle column (Knauer, Berlin, Germany). The mobile phase contained 0.1 M sodium acetate, 6.25% methanol, 1.5% tetrahydrofurane, pH 6.95 and was perfused at a flow rate of I mLlmin. A linear /,'Tadient system was used to clean the column afier elution of glutamate. This involved switching to 100% methanol for 2 min before switching back to the original acetate buffer. The excitation wavelength in the fluorescence detector (Hitachi FIOOO, Tokyo, Japan) was set at 370 nm and the emission cut off filter was set at 450 nm. The limit of detection was 0.5 pmoVsample for glutamate (Morari et aI., 1994) .
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The GABA assay was based on precolumn derivatization of a 10 J.lL sample with 0-phtaldialdehydeft-butylthiol reagent and separation by reversed-phase HPLC on a Nucleosil3 CI8 column perfused under isocratic conditions at the flow rate of 0.8 mUmin. The mobile phase was 0.15 M sodium acetate, I mM EDT A, 50% acetonitrile, pH 5.4. The BAS LC4B electrochemical detector (Bioanalytical Systems, West Lafayeue, fN) was set at +0.75 Y. The limit of detection was 50 fmolfsample (Morari et aI., 1994) .
Statistical Analysis
All data in the graphs are expressed as mean ± standard error of the mean. Tabular data are expressed as mean ± standard deviation. Data analysis for all measurements except NAAG was performed using SPSS software (version 11.5). Alpha level for Type I error was set at 0.05 for rejecting null hypotheses.
Fluid percussion injury magnitudes (in ATM) and temperature measurements were analyzed using separate one-way ANOY A between treatment groups. Amino acid concentrations from the four groups at the 0-15 min post injury dialysate samples were analyzed with one-way ANOY A. Post hoc comparisons were made using the Dunnett t (two-sided) test comparing each treatment (vehicle, ZJ-43, ZJ-43+LY341495) with the probe-reinsertion control. A similar analysis was also performed on the \5-30 minute post injury dialysate samples.
Data analysis for the NAAG microdialysis was performed using a linear mixed-effects model of drug and time (sample) fit by restricted maximum likelihood estimation (REML) using library nlme in R (version 2.1.\,2005). Five microdialysate samples could not be analyzed due to sample collect problems. Analysis oflonb~tudinal data necessarily involves inter-correlated observations within individuals but missing observations cause conventional repeated-measures ANOY A to fail or delete entire cases; the mixed-effects model enables fiuing of both fixed and random terms despite data loss (Pinheiro & Bates, 2000) . This model 9 takes into accountthc loss of degrees of freedom in estimating the mean and produces unbiased estimating equations for the variance parameters (Smyth and Yerbyla, 1996) .
RESULTS
Fluid percussion injury magnitudes between !,' TOUPS ranged from 2.27 to 2.31 ATM. Mean rectal temperatures of groups ranged from 36.9 to 37.2"C at the time ofTSI and at the time of the final microdialysis sample. There were no significant differences between groups in injury magnitude or rectal temperature values (Table I) . T he modi fied mierodia lysis placement technique achieved accumlc and consislcnllargeling (lflh" probe lip inlo the dorsal hippocampus CA3 region in all anllnals. Figure I shows Ihe probe lrack in a typical ani mal post-i njury. Dialysate GABA levels in the Z1-43 treatment group were not significantly different from control (p '" 0.32 Dunnett) in the 0-15 min post-injury dialysate sample. Thus, at the first sample time point after TBI, ZJ-43 treatment reduced the injury-induced elevation in dialysate GAB A levels. Similar to glutamate, dialysate GABA levels in the ZJ-43 + LY341495 treatment group were significantly higher than probereinsertion controls (p '" 0.03 Dunnett). Thus, addition of L Y341495, the Group II mGluR antagonist, reversed the protective effect of ZJ-43 on dialysate GABA levels in the dorsal hippocampus.
DISCUSSION
We examined four neurotransmitters (NAAG, glutamate, aspartate, and GAB A) in microdialysis samples collected from the rat dorsal hippocampus after lateral fluid percussion TBI and found a significant increase in the dialysate levels of all four neurotransmitter levels. However, a single intraperitoneal injection of the novel NAAG peptidase inhibitor, ZJ-43 (50 mglkg) was associated with a robust increase in dialysate NAAG levels and significantly reduced the elevation of glutamate, aspartate and GABA levels after TBI. Moreover, the group II mGluR selective antagonist, LY341495, successfully reduced the effects of ZJ-43 on dialysate glutamate and GABA levels. This latter finding indicates that the effects of NAAG peptidase inhibition on glutamate and GABA are likely mediated by activation of Group II mGluRs.
Microdialysis studies in TBI:
Using microdialysis, other investigators have demonstrated changes in extracellular levels of energyrelated metabolites and amino acids in hippocampal and cortical regions following TBI (Faden et aI., 1989; Katayama et aI., 1990; Globus et aI., 1995) . However, the microdialysis techniques used in experimental brain injury models varied among studies. In one study, the microdialysis probe was inserted into the CAl and dentate areas in the hippocampus through a burr hole separate from a near midline craniotomy used for administration of a fluid percussion injury (Katayama et aI., 1990) . In another study, the dialysis probe was placed into the parietal cortex posterior and ipsilateral to the fluid percussion craniotomy (Globus et aI., 1995) . Other studies inserted the dialysis probe directly through the fluid percussion craniotomy afier administration of the lateral fluid percussion TBI (Dixon et aI., 1996;  Bentzer et aI., 2000; Alves et aI., 2005) . Herein, we modified the microdialysis technique in combination for use with the fluid percussion rat trauma model by making a small burr hole in the temporal bone and then inserting the modified guide cannula and dialysis probe at a 45 degree angle from vertical with the probe's tip protruding directly in the CA3 region of the dorsal hippocampus ipsilateral to TBI. There may be at least two advantages with this modification. First, the probe's dialysis membrane was directly positioned just under the brain impact site. This approach should provide sensitive detection of alterations in the traumatized hippocampus. Moreover, inserting the probe through a separate burr hole in the temporal bone leaves the dura intact at the site of fluid percussion impact and thus minimizes any probe interference with the site of fluid percussion impact. Histological examination or brains Ii'om the present study indicated that the microdialysis probe reliably reached the targeted C A3 region of the dorsal hippocampus.
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Factors influencing dialysate amino acid neurotransmitter levels:
In the anesthetized preparation used in the present study, microdialysis probes typically require a I hour stabilization period before analyte concentration in the fluid returns to levels thought to represent nonnal physiological levels in the extracellular space. As such there is a potential problem with withdrawing the probe from the brain just prior to TBI and reinserting it immediately after the fluid percussion impact down the same track. An alternative is to leave the probe in the brain, but this is likely to cause local tissue shearing against the dialysis probe during brain movement at the time of fluid percussion impact (Globus et aI., 1995) . Moreover, measurement of neurotransmitters by microdialysis has many potential artifacts, not the least of which is the trauma induced by the probe implantation itself. The initial probe insertion was associated with a large but transient increase in dialysate amino acid neurotransmitter levels (data not shown).
However, our control experiments to assess the effects of probe removal and reinsertion (i.e. probereinsertion control) in uninjured rats found only a small increase in dialysate glutamate levels following probe reinsertion that rapidly returned to baseline within 15 minutes. This reinsertion method has been successfully perfonned by a number of investigators (Katayama et aI., 1990; Globus et aI., 1995; Kawamata et aI., 1995) as well as in our own laboratory.
Glutamate excitotoxicity is a significant detenninant ofTBI pathophysiology. Numerous laboratory studies (Faden et aI., 1989; Katayama et aI., 1990; Nilsson et aI., 1990) and several clinical studies (Zauner et aI., 1996; Bullock et aI., 1998; Koura et aI., 1998) have documented an excessive glutamate release following TBI. Experimental cerebral ischemia is also associated with a large, rapid increase in extracellular glutamate (Choi and Rothman, 1990; Benveniste et aI., 1984; Globus et aI., 1988 Globus et aI., , 1991 . The mab'11itude and the temporal profile of these increases varied among studies, which may be due differences in microdialysis methods and the fact that the microdialysis sampling was perfonned in different brain regions (i.e., hippocampus, cortex, etc. and probe implantation adjacent to or directly within the injury site). In the present study, -20-fold increases in dialysate glutamate levels were observed in the first sample collected after impact (0-15 min sample) and returned to near baseline 15-30 min post-injury. It is importanllo consIder Ihali()lIowing TBllhere arc pCllential "secondary"' sources of glutamate including blood (via BBB leakage), inhibition or reversal of glutamate transporters (predominantly on astrocyles) , and hydrolysis ofNAAG (Hillered et al.. 2005 : Zhou et aI., 2005 . NAAG peptidase inhibition would li kely reduce both syoaptic vesicular release and glutamate from NAAG hydrolysis . Since ZJ-43 did not completely eliminate the eleva tion in extracellular glutamate. the data suggest other seconda ry sources ma y have contributed to the elevated glutamate measured post TBI.
Our data also documented a smaller magnitude, transient elevation in the dialysate levels of aspartate after TBI. This is similar to the previous descriptions of injury-related alterations in extracellular levels of neurotransmitter amino acids (Faden et aI., 1989; Nilsson et aI., 1990; Palmer et aI., 1994) . The present results support the potential role of glutamate and aspartate as mediators of excitotoxic cell injury following TB I. An elevation in dialysate GABA levels (-25-fold) similar to that of dialysis glutamate levels was observed immediately after injury. Microdialysis sampling of GAB A after TBI or ischemia has not been previously reported. The exact mechanism by which both the potentially cylotoxic (i.e., glutamate and aspartate) and protective (i.e., GABA) amino acid neurotransmitters increase in the extracellular space at the same time after trauma will require further studies although speculation that such elevations may be reflect changes in cellular flux or breakdown of the blood brain barrier or both (Palmer et aI., 1994) . Another possible explanation is that dialysate GABA levels may also be a sensitive index of acute excitoxicity and the pronounced elevation in GABA in the dorsal hippocampus may be mediated by excessive local NMDA receptor activation (Zeevalk and Nicklas, 1993; Palmer et aI., 1994) .
Moreover, the elevation in GABA could possibly blunt the excitatory actions associated with increased levels of glutamate and aspartate (Palmer et aI., 1994) .
Potentiating the effect ofNAAG by peptidase inhibition:
NAAG serves as a co-transmitter with several small amino acid transmitters, including glutamate and GABA (Coyle et aI., 1997; Neale et aI., 2000) . serves as a modulator of neurotransmitter release (Bischofberger and Schild, 1996; Zhao et aI., 2001; Xi et aI., 2002; Garrido-Sanabria et aI., 2004) . Little 15 is known about the alteration ofNAAG level following TBl. Our data indicate a large increase (-25-fold) in dialysate NAAG levels 15 minute after TBI, which returned to near baseline 45-60 minute post-injury.
A series of novel NAAG peptidase inhibitors have been shown to act as potent neuroprotective or neuroactive agents through attenuating the influence of glutamatergic transmission under pathological conditions (reviewed in Neale et aI., 2005; Zhou et aI., 2005) . Among them, the urea-based NAAG analogue, ZJ-43, was shown to act as a potent inhibitor ofNAAG peptidases, GCP 11 (K, ~0.8 nm) and GCP 111 (Ki =23 nm) that breakdown NAAG following synaptic release . A previous study performed by this group showed that intraperitoneal administration ofZJ-43 at the 50 mg/kg dose significantly reduced both neuronal and astrocyte damage in the dorsal hippocampus following TBI (Zhong et aI., 2005) . In the present study, a single intraperitoneal injection of ZJ-43 at the 50 mglkg dose was associated with a robust and prolonged increase in dialysate NAAG levels for over 2 hours and this paralleled a significant reduction in the TBI-induced release of glutamate, aspartate and GABA.
Reversal of the effects of ZJ-43 by L Y341495: Possible mechanisms and implications:
The selective Group 11 mGluR antagonist, L Y341495, blocked the effects of ZJ-43 on dialysate glutamate and GABA levels in the dorsal hippocampus. However, the inability of L Y341495 to reverse the ZJ-43-induced reduction in dialysate aspartate levels suggests a smaller neuronal pool for this amino acid and/or a lack of Group 11 mGluRs located on aspartate containing elements in the dorsal hippocampus. Another possibility is that bre"kdown ofNAA by aspa11oacyc1ase Illay contribute to the SI'urce of excessive as partate. If so. inhibition of NAAG peptidase by Z.I-43 would reduce aspartate levcls by reducing available NAA and the addition of LY341495 would not block the etlc ct, Z.I-43. These data are consistent with previous findings showing that the protective effects on neurons and astrocytes were completely lost when LY341495 was co-administered with ZJ-43 (Zhong et aI., 2005) . LY341495 was similarly effective in blocking the therapeutic effects ofZJ-43 in animal models of pain and schizophrenia (Yamamoto et aI., 2004; Olszewski et aI., 2004) . Since ZJ-43 was associated with a significant rise in dialysate NAAG levels and NAAG is selective for mGluR3, the protection is likely due to the enhanced activation of this group II subtype. Thus, the present findings strongly suggest that the protection afforded by ZJ-43 is mediated by the activation of group II mGluRs in the dorsal hippocampus.
Pharmacological activation of Group II mGluRs provides neuronal protection in il1l'ill"o injury cell injury models (Allen et aI., 1999) and ill I'il'o TBI models (Allen et aI., 1999; Zwienenberg et aI., 2001 ).
Furthermore, direct application ofNAAG, which activates Group II mGluRs, reduces NMDA-induced toxicity in cultured mouse cortical cells (Bruno et aI., 1998) . Pre-stroke administration of the NAAG peptidase inhibitor (2-PMPA) in rats decreases dialysate glutamate and lesion volume and improves behavioral performance following transient middle cerebral artery occlusion in rats (Slusher et aI., 1999) .
The ability ofNAAG to activate presynaptic mGluRs and inhibit glutamate release (Xi et aI., 2002; Garrido-Sanabria et aI., 2004) further supports the conclusion that NAAG peptidase inhibitors such as ZJ-43 exert their therapeutic effects by elevating extracellular NAAG levels in the dorsal hippocampus which then activate local mGluR3.
Other studies have shown that NAAG peptidase inhibitors provide benefit in a number of models including amyotrophic lateral sclerosis (Ghadge et aI., 2003) , diabetic neuropathy (Zhang et aI., 2002) , allodynia (Yamamoto et aI., 2001) , neuropathic and inflammatory pain (Yamamoto et aI., 2004) , and phencyclidine induced schizophrenia-like behaviors (Olszewski et aI., 2004) . Excess glutamate release has been implicated in each of these models of human pathological conditions. These applications have supported the contention that NAAG peptidase is a significant therapeutic target.
The strategy of inhibiting NAAG peptidase and subsequent NAAG hydrolysis may afford brain protection from TBI in several ways. First, inhibition ofNAAG peptidase activity, resulting in an increase of endogenous NAAG, could provide neuroprotection through activation of group II metabotropic receptors and subsequent reduction in the release of glutamate (Neale et aI., 2005) . Second, blockade of NAAG peptidases could have neuroprotectivc effects by reducing a secondary source of glutamate as a byproduct ofNAAG hydrolysis (Slusher et al. 1999) . The data presented here and elsewhere argue against this interpretation inasmuch as the NAAG levels are up to \0 fold lower than the glutamate levels and thus not possibly responsible for the changes in the glutamate levels. Third, astrocytes also express group II mGluRs (Wroblewska et aI., 1998; Ferraguti et aI., 2001; Aronica et aI., 2003) . Selective activation of Group II mGluRs on astrocytes stimulates the release ofneuroprotective factors (Bruno et aI., 1998) . Activation of Group II mGluRs on astrocytes also positively modulate the expression of glutamate transporters, increasing the ability of astrocytes to remove glutamate from the synapse (Aronica et aI., 2003) . Finally, inhibition ofNAAG peptidase would also decrease a synaptic source ofNAA which is transported into astrocytes along with sodium. Thus, reduced transport ofNAA would likely reduce the sodium load on astrocytes and limit potential mechanisms of astrocyte edema. Thus, blockade ofNAAG peptidases offers a multi-fold potential for neuroprotection against glutamate excitotoxicity and subsequently reduces both astrocyte and neuronal damage under pathological conditions. This strategy represents a novel method of reducing the damaging glutamate release associated with TBI by augmenting the brain's natural endogenous system of controlling glutamate release via presynaptic feedback on mGluR3 by the NAAG peptide.
In summary, treatment with the NAAG peptidase inhibitor ZJ-43 produced significant protection that increased dialysate NAAG levels and decreased excessive dialysis levels of glutamate and other neurotransmitters such as aspartate and GABA associated with TBI. The data presented herein support the hypothesis that inhibition ofNAAG peptidase may decrease the magnitude and duration of excitotoxic events associated with TBI and represent a new potential therapeutic approach to TBI treatment. were not significantly different from probe-reinsertion control in the first post-injury dialysate. Thus, ZJ-43 administration was associated with a significant reduction in the elevation of glutamate levels after TBI.
Dialysate glutamate levels in the ZJ-43 + L Y341495 group were significantly elevated compared to control 27 indicating that L Y342495 reversed the protective effect of ZJ-43 on dialysate glutamate levels in the dorsal hippocampus. • signifies p < 0.05 compared to probe-reinsertion control.
Fib'lJre 4. Time course of dialysate aspartate levels.
Either vehicle, ZJ-43, or ZJ-43 + LY342495 was administered 15 min prior to TBI. Dialysate aspartate levels in the vehicle-treatment group were significantly elevated compared to probe-reinsertion controls in the first post-injury dialysate sample. Dialysate aspartate levels in the ZJ-43 treatment group and the ZJ-43 + L Y341495 group were not significantly different from probe-reinsertion control in the first post-injury dialysate sample. Thus, ZJ-43 administration was associated a significant reduction in the elevation of aspartate levels after TBI. • signifies p < 0.05 compared to probe-reinsertion control. Vehicle, ZJ-43, or ZJ-43 + LY342495 was administered 15 min prior to TBI. Dialysate GABA levels in the vehicle-treatment group treatment group were significantly elevated compared to probe-reinsertion controls in the first post-injury dialysate sample. Dialysate GABA levels in the ZJ-43 treatment group were not significantly different from probe-reinsertion control in the first post-injury dialysate sample. Thus, ZJ-43 administration was associated a significant reduction in the elevation of GABA levels after TBI.
Dialysate GABA levels in the ZJ-43 + L Y341495 group were significantly elevated compared to control indicating that L Y342495 reversed the protective effect of ZJ-43 on dialysate GABA levels in the dorsal hippocampus. • signifies p < 0.05 compared to probe-reinsertion control. .:. 
28
